Researchers Want to Combine Cannabis and Psilocybin into Single Medical Treatment

In 2021, CaaMTech received its first patent for the research. The company “develops pharmaceutical drugs for mental health conditions like depression and obsessive-compulsive disorder” and is now “researching the therapeutic value of psilocybin in combination with cannabinoids.” An article published Wednesday on the website Greenstate explains that the company “develops pharmaceutical drugs for mental health conditions like depression and obsessive-compulsive disorder,” and is now “researching the therapeutic value of psilocybin in combination with cannabinoids.””Through their research, CaaMTech has isolated derivatives of psilocybin, cannabinoids, and terpenes,” Greenstate explained.In the 2021 announcement of the patent, CaaMTech founder and CEO, Dr. Andrew Chadeayne said that the company’s “goal from Day 1 has been to capture as much of CaaMTech’s scientific innovation as possible in our intellectual property portfolio as we develop the next generation of psychedelic drugs.””The allowance of our first patent application has given a shot of energy to the team that has worked diligently over these past four years to bring it to the finish line,” Chadeayne said in the announcement. This is a good start, as there are hundreds of applications to be prosecuted. “‘Compositions & methods comprising a Psilocybin Derivative’ covers, among other subjects, the synergistic modulatory effect of cannabinoids when administered with a serotonin-agonist. CaaMTech’s research has shown that cannabinoids and psychedelic typtamines work together to produce their effects. CaaMTech, in doing so, has demonstrated that two drugs, once declared by the United States Federal Government as having ‘no medical value’, can be used to treat some of world’s most difficult mental health issues. The outlet reported that these steps, along with policy work, will create wider access lanes to patients seeking science-based psychedelic treatments. As MJBizDaily explained, there are “serious obstacles to creating a combo compound.””Cannabinoids and psychedelics act on different receptors in the brain. Cannabinoids like THC bind primarily to CB1 cannabinoid; CBC binds primarily CB2 receptor. The outlet reported that psilocybin and other psychedelics bind to 5-HT2A receptors. But research has shown that CBD can also bind to serotonin. And that when combined with a CB2 receptor, it can achieve things that neither receptor alone can. Cannabis combined with psychedelics was found to shrink breast cancer tumors significantly.